N/A N=20 Other

Innovations in HIV Testing (TI)

Human Immunodeficiency Virus

Bottom Line

View on ClinicalTrials.gov: NCT03271424 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jan 2018

Primary outcome: Primary: Qualitative Summaries of Participant Experience in Focus Group Discussions — 100; 7; 26; 10 number of times reported in FGD

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Oraquick HIV Self Test - Choice (Diagnostic_test); Atomo HIV Self Test - Choice (Diagnostic_test); Oraquick HIV Self Test and Atomo HIV Self Test - Both (Diagnostic_test)
Age: Adult · 18+ yrs
Sex: All
Sponsor: University of North Carolina, Chapel Hill
Primary completion: Jun 2016

Outcome Measures

Outcome	Result	p-value
PRIMARY Qualitative Summaries of Participant Experience in Focus Group Discussions	100; 7; 26; 10; 29; 12	—
PRIMARY Quantitative Summaries of Participants Experience in Observation Sessions	19; 19; 30; 8; 16; 14	—

Summary

The investigators propose to improve HIV prevention and care through expanding HIV testing options to include self-testing for young women, their peers and their sex partners, and by facilitating linkage to care.

Eligibility Criteria

FGD Inclusion Criteria:

Females and males aged 18 - 24
Able and willing to provide informed consent
Residing in the selected villages

Observation Inclusion Criteria:

Females and males aged 18 -24
Able and willing to provide informed consent
Residing in the selected villages
Not known to be HIV positive (not reporting a previous positive test)

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03271424). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.